| Literature DB >> 29760073 |
Kwang Soo Kim1,2, Paul C Marcogliese1,2, Jungwoo Yang1,2, Steve M Callaghan1,2, Virginia Resende1,3, Elizabeth Abdel-Messih1,2, Connie Marras4,5, Naomi P Visanji4,5, Jana Huang5, Michael G Schlossmacher2,6,7, Laura Trinkle-Mulcahy1,3, Ruth S Slack1,2, Anthony E Lang4,5,8, David S Park9,2.
Abstract
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in both familial and sporadic Parkinson's disease (PD), yet its pathogenic role remains unclear. A previous screen in Drosophila identified Scar/WAVE (Wiskott-Aldrich syndrome protein-family verproline) proteins as potential genetic interactors of LRRK2 Here, we provide evidence that LRRK2 modulates the phagocytic response of myeloid cells via specific modulation of the actin-cytoskeletal regulator, WAVE2. We demonstrate that macrophages and microglia from LRRK2-G2019S PD patients and mice display a WAVE2-mediated increase in phagocytic response, respectively. Lrrk2 loss results in the opposite effect. LRRK2 binds and phosphorylates Wave2 at Thr470, stabilizing and preventing its proteasomal degradation. Finally, we show that Wave2 also mediates Lrrk2-G2019S-induced dopaminergic neuronal death in both macrophage-midbrain cocultures and in vivo. Taken together, a LRRK2-WAVE2 pathway, which modulates the phagocytic response in mice and human leukocytes, may define an important role for altered immune function in PD.Entities:
Keywords: LRRK2; Parkinson’s disease; WASF2; WAVE2; microglia
Mesh:
Substances:
Year: 2018 PMID: 29760073 PMCID: PMC5984500 DOI: 10.1073/pnas.1718946115
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205